The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate ophthalmic gel, 0.38% (BID and TID) for the treatment of postoperative inflammation and pain following cataract surgery.
The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate ophthalmic gel